Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Persistent hiccup condition that started 3 days after the last dose of Shingrix; spasm in her thoracic region; This non-serious case was reported by a nurse via call center representative and described the occurrence of hiccups in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on an unknown date). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, 3 days after receiving Shingrix, the patient experienced hiccups (Verbatim: Persistent hiccup condition that started 3 days after the last dose of Shingrix) and spasms (Verbatim: spasm in her thoracic region). The outcome of the hiccups and spasms were not resolved. It was unknown if the reporter considered the hiccups and spasms to be related to Shingrix. It was unknown if the company considered the hiccups and spasms to be related to Shingrix. Additional Information: GSK receipt Date: 23-JUN-2025 The nurse reported that there was a female patient (over 50 years) that was experiencing some type of spasm in her thoracic region, causing a certain type of hiccup condition. It was persistent and started 3 days after the last dose of Shingrix. At the moment of the call patient's details and dates were not available. The health care professional requested to be contact buck in order to provide all information missing please. The vaccine administration facility was the same as primary reporter.